8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): July 14, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Delaware                      000-28876               22-2407475
           --------                      ---------               ----------
(State or other jurisdiction of (Commission File Number) (IRS Employer
 incorporation or organization) Identification No.)


           225 Long Avenue
         Hillside, New Jersey                             07205
         --------------------                             -----
(Address of principal executive offices)                (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)






Item 5.       Other Events and Regulation FD Disclosure.

                  On July 14, 2004, Integrated BioPharma, Inc., a Delaware
corporation (the "Company"), issued a press release announcing the mutual
execution of an agreement with Hauser Inc. to acquire the Hauser Contract
Research Organization.  This transaction, which is subject to court approval, is
scheduled to close in September 2004.  The press release is attached as an
exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on July 14, 2004






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  July 14, 2004              INTEGRATED BIOPHARMA, INC.


                                  By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer







                                  Exhibit Index

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on July 14, 2004

EX-99

FOR IMMEDIATE RELEASE                                Contact: Eric Friedman
July 14, 2004                                        Investor Relations
                                                     (973) 926-0816

 Integrated BioPharma Agrees to Acquire Hauser Contract Research Organization,
                           Continuing Expansion Plan

Hillside, N.J., July 14, 2004--Integrated BioPharma, Inc. (AMEX:INB) announced
the mutual execution of an agreement with Hauser Inc. to acquire the Hauser
Contract Research Organization (Hauser CRO). The transaction, which is subject
to court approval, is scheduled to close in September 2004.

As an ongoing business, the Hauser CRO is expected to provide revenues, an
established customer base and expanded analytical capabilities in support of
INB's growth and expansion goals. The Hauser CRO, together with Paxis
Pharmaceuticals, Inc., another wholly owned subsidiary, will give INB a complete
capability, from inception to commercialization, to create Active Pharmaceutical
Ingredients (API) for itself and customers.

Hauser CRO is a world leader in the extraction, isolation, purification and
synthetic modification of natural products from plant, marine and microbial
sources. Hauser CRO provides small scale API Production for clinical trials
through commercial applications. In addition, Hauser CRO provides research,
process development, analytical services, manufacturing, compliance services and
consulting to companies in pharmaceutical, dietary supplement and fine chemical
industries.

The Hauser CRO acquisition complements and extends INB's expansion into the
supply of Active Pharmaceutical Ingredients. Paxis Pharmaceuticals, Inc., a
wholly owned subsidiary, is a world leader in the supply of Paclitaxel, the
leading anticancer compound. Combined with the Hauser CRO, Paxis now has a
substantial platform to leverage its modern and recently updated manufacturing
plant into development and manufacturing of a variety of API products, meeting
customers' needs as well as its own internal needs. Combined, the companies will
operate 6 GMP suites. Paxis will be able to provide complete development of API
from concept to production.

INB CEO E. Gerald Kay commented that "The CRO acquisition enhances our position
as a manufacturer of Active Pharmaceutical Ingredients. This should provide for
additional opportunities for both taxane based novel drug candidates and other
non taxane based naturally derived and semi-synthetic pharmaceuticals." INB
serves the pharmaceutical, biotech and nutraceutical industries. Through several
wholly owned subsidiaries, INB develops, manufactures and distributes more than
130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc., develops
and operates a state-of-the-art GMP facility for the production and sale of
paclitaxel and related drugs. Through its biotech subsidiary, NuCycle Therapy,
Inc., INB is developing human therapeutics and preventive cancer compounds in
transgenic plants. Further information is available at www.iBioPharma.com.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could affect the
company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.